Summary by Moomoo AI
ARK Investment Management LLC, an investment adviser based in Delaware, United States, has filed an amended Schedule 13G with the United States Securities and Exchange Commission on January 10, 2024, indicating a significant ownership stake in CRISPR Therapeutics AG. The filing, which reflects the state of ownership as of December 31, 2023, shows that ARK Investment Management LLC has beneficial ownership of 8,536,104 shares of CRISPR Therapeutics' common stock, representing 10.75% of the class. The investment firm has sole voting power over 8,057,147 shares and shared voting power over 244,377 shares. Additionally, ARK Investment Management LLC possesses sole dispositive power over the entire 8,536,104 shares it owns. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.